Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alicia Rossi is active.

Publication


Featured researches published by Alicia Rossi.


Antimicrobial Agents and Chemotherapy | 2002

Plasmidic Extended-Spectrum β-Lactamases in Vibrio cholerae O1 El Tor Isolates in Argentina

Alejandro Petroni; Alejandra Corso; Roberto G. Melano; María Luisa Cacace; Ana María Bru; Alicia Rossi; Marcelo Galas

ABSTRACT Since 1992 there have been seven major outbreaks of cholera in Argentina. Susceptibility analysis of 1,947 isolates (40% of reported cases) of Vibrio cholerae O1 biotype El Tor suggested the presence of extended-spectrum β-lactamases (ESBLs) in 28 isolates. Because of their different susceptibility profiles, V. cholerae isolates M1502, M1516, M1573, and M3030 (all of which are of the Ogawa serotype) were selected for the present study. By susceptibility analysis, isoelectric focusing, and PCR-based restriction fragment length polymorphism analysis, CTX-M-type enzymes were identified in three isolates, whereas a PER-2-type enzyme, in addition to a TEM-1-like enzyme, was identified in the other isolate. The presence of these ESBLs in V. cholerae isolates resulted in MICs well below those commonly observed for members of the family Enterobacteriaceae. Genes that encode both ESBLs were transferred to Escherichia coli by conjugation, together with all determinants of resistance to non-β-lactam antibiotics (gentamicin, kanamycin, and sulfamethoxazole for all isolates; amikacin and streptomycin for three isolates; trimethoprim, tetracycline, and chloramphenicol for two isolates). Plasmid profile analysis and Southern blotting revealed the presence of single plasmids of about 150 kb in the four V. cholerae isolates and their respective transconjugants and revealed that the plasmids harbored genes encoding CTX-M-type or PER-2-type ESBLs. These results strongly suggest the broad spread of these ESBLs among genera belong to families other than the Enterobacteriaceae.


Antimicrobial Agents and Chemotherapy | 2004

CARB-9, a Carbenicillinase Encoded in the VCR Region of Vibrio cholerae Non-O1, Non-O139 Belongs to a Family of Cassette-Encoded β-Lactamases

Alejandro Petroni; Roberto Melano; Héctor A. Saka; Alicia Garutti; Laura Mange; Fernando Pasteran; Melina Rapoport; Mariana Miranda; Diego Faccone; Alicia Rossi; Paul S. Hoffman; Marcelo Galas

ABSTRACT The gene blaCARB-9 was located in the Vibrio cholerae super-integron, but in a different location relative to blaCARB-7. CARB-9 (pI 5.2) conferred β-lactam MICs four to eight times lower than those conferred by CARB-7, differing at Amblers positions V97I, L124F, and T228K. Comparison of the genetic environments of all reported blaCARB genes indicated that the CARB enzymes constitute a family of cassette-encoded β-lactamases.


Revista Panamericana De Salud Publica-pan American Journal of Public Health | 2000

Impacto de Streptococcus pneumoniae en las neumonías del niño latinoamericano

Maria Hortal; Raúl Ruvinsky; Alicia Rossi; Clara Inés Agudelo; Elizabeth Castañeda; Cristina Brandileone; Teresa Camou; Rosario Palacio; Gabriela Echaniz; José Luis Di Fabio

La neumonia adquirida en la comunidad es una de las principales causas de morbilidad y mortalidad en la infancia. Estudios realizados en paises en desarrollo indican que los cuadros de neumonia mas graves se asocian a causas bacterianas, con predominio de Streptococcus pneumoniae, seguido por Haemophilus influenzae tipo b. El manejo de esas infecciones en los menores de 2 anos se ve dificultado por la carencia de vacunas apropiadas y por la disminucion de la susceptibilidad de S. pneumoniae a la penicilina y a otros antibioticos. En 1993, por iniciativa del Sistema Regional de Vacunas (SIREVA) de la Organizacion Panamericana de la Salud y con la financiacion de la Agencia Canadiense para el Desarrollo Internacional (Canadian International Development Agency: CIDA), se diseno un estudio para identificar los tipos capsulares de S. pneumoniae que causan enfermedad invasora en los ninos latinoamericanos menores de 5 anos, con el proposito de determinar tanto la composicion ideal de una vacuna conjugada que pudiera emplearse en la Region como la susceptibilidad a la penicilina de los aislados de S. pneumoniae. La iniciativa fue aceptada por Argentina, Brasil, Colombia, Chile, Mexico y Uruguay. En este informe se analiza la informacion sobre la neumonia por S. pneumoniae generada en los paises participantes. Se captaron 3 393 ninos con infecciones sistemicas por S. pneumoniae, de las cuales 1 578 correspondian a neumonias. El analisis se concentro en los 1 409 casos de neumonia de Argentina, Brasil, Colombia, Mexico y Uruguay. La distribucion por edades evidencio un franco predominio de los menores de 2 anos (63,8%). Se identificaron 12 tipos capsulares prevalentes, de los cuales los serotipos 14, 5 y 1 ocuparon los tres primeros lugares en la mayoria de los paises. En el periodo 1993-1998, la resistencia a la penicilina aumento en los cinco paises; al comienzo del estudio, los mayores porcentajes correspondieron a Mexico (47,0%) y los menores a Colombia (12,1%). La resistencia a la penicilina se asocio con un reducido numero de serotipos capsulares, fundamentalmente el 14 y el 23F, el primero resistente a la penicilina y a la trimetoprima-sulfametoxazol, y el segundo multirresistente. La frecuencia de la resistencia a la trimetoprima-sulfametoxazol fue elevada en todos los paises y el valor maximo correspondio a Argentina (58,0%). La disminucion de la susceptibilidad al cloranfenicol tuvo baja frecuencia, salvo en Colombia (23,4%). La resistencia a la eritromicina fue baja en todos los paises y todos los aislados fueron sensibles a la vancomicina.Community-acquired pneumonia is one of the leading causes of infant morbidity and mortality. Studies conducted in developing countries indicate that the most serious symptoms of pneumonia are associated with bacterial causes, mainly Streptococcus pneumoniae, followed by Haemophilus influenzae type b. Managing those infections in children under two years of age is hindered by the lack of appropriate vaccines and by the decreased susceptibility of S. pneumoniae to penicillin and other antibiotics. In 1993, at the initiative of the Regional System for Vaccines of the Pan American Health Organization, and with funding from the Canadian International Development Agency, a study was designed to identify the S. pneumoniae capsular types that cause invasive disease in Latin American children under 5 years of age. The objective of the study was to determine the ideal composition of a conjugate vaccine that could be used in Latin America, and the penicillin susceptibility of the S. pneumoniae isolates. The initiative was undertaken in Argentina, Brazil, Chile, Colombia, Mexico, and Uruguay. This report analyzes the information that the participating countries generated on pneumococcal pneumonia. A total of 3,393 children were found with systemic S. pneumoniae infections, of which 1,578 corresponded to pneumonias. The analysis focused on 1,409 cases of pneumonia in Argentina, Brazil, Colombia, Mexico, and Uruguay. Of the children, 63.8% of them were under two years of age. Twelve prevalent capsular types were identified, of which serotypes 14, 5, and 1 were the three most common in the majority of the countries. At the beginning of the study the highest level of penicillin resistance was found in Mexico (47.0%), and the lowest in Colombia (12.1%). Over the 1993-1998 period, resistance to penicillin increased in the five countries. Penicillin resistance was associated with a small number of capsular serotypes, mainly 14 and 23F. The first of those serotypes was resistant to penicillin and to trimethoprim-sulfamethoxazole, and the second was multiresistant. The frequency of resistance to trimethoprim-sulfamethoxazole was high in all of the countries; Argentina had the highest level, 58.0%. A decrease in susceptibility to chloramphenicol was uncommon, except in Colombia, where there was a resistance level of 23.4%. Resistance to erythromycin was low in all the countries, and all the isolates were susceptible to vancomycin.


Antimicrobial Agents and Chemotherapy | 2002

New Carbenicillin-Hydrolyzing β-Lactamase (CARB-7) from Vibrio cholerae Non-O1, Non-O139 Strains Encoded by the VCR Region of the V. cholerae Genome

Roberto G. Melano; Alejandro Petroni; Alicia Garutti; Héctor A. Saka; Laura Mange; Fernando Pasteran; Melina Rapoport; Alicia Rossi; Marcelo Galas

ABSTRACT In a previous study, an analysis of 77 ampicillin-nonsusceptible (resistant plus intermediate categories) strains of Vibrio cholerae non-O1, non-O139, isolated from aquatic environment and diarrheal stool, showed that all of them produced a β-lactamase with a pI of 5.4. Hybridization or amplification by PCR with a probe for blaTEM or primers for blaCARB gene families was negative. In this work, an environmental ampicillin-resistant strain from this sample, ME11762, isolated from a waterway in the west region of Argentina, was studied. The nucleotide sequence of the structural gene of the β-lactamase was determined by bidirectional sequencing of a Sau3AI fragment belonging to this isolate. The gene encodes a new 288-amino-acid protein, designated CARB-7, that shares 88.5% homology with the CARB-6 enzyme; an overall 83.2% homology with PSE-4, PSE-1, CARB-3, and the Proteus mirabilis N29 enzymes; and 79% homology with CARB-4 enzyme. The gene for this β-lactamase could not be transferred to Escherichia coli by conjugation. The nucleotide sequence of the flanking regions of the blaCARB-7 gene showed the occurrence of three 123-bp V. cholerae repeated sequences, all of which were found outside the predicted open reading frame. The upstream fragment of the blaCARB-7 gene shared 93% identity with a locus situated inside V. choleraes chromosome 2. These results strongly suggest the chromosomal location of the blaCARB-7 gene, making this the first communication of a β-lactamase gene located on the VCR island of the V. cholerae genome.


Revista Panamericana De Salud Publica-pan American Journal of Public Health | 1999

Vigilancia de la resistencia a los antibacterianos en Argentina. Programa WHONET, 1995-1996

Alicia Rossi; Marta Tokumoto; Marcelo Galas; Rolando Soloaga; Alejandra Corso

La Organizacion Mundial de la Salud ha puesto en marcha un programa para la vigilancia de la resistencia a los antibacterianos, denominado WHONET, que se desarrollo en Argentina mediante una red de 23 laboratorios de instituciones hospitalarias publicas y privadas someti-dos a programas nacionales e internacionales de control de calidad. Entre enero de 1995 y di-ciembre de 1996 se determino por el metodo de difusion en agar la sensibilidad a los antibacte-rianos de 16 073 aislados clinicos consecutivos, siguiendo las recomendaciones del Comite Nacional de Estandares para Laboratorios Clinicos (National Committee for Clinical Labo-ratory Standards:NCCLS) de los Estados Unidos de America. Mas de la mitad de los aisla-dos urinarios de Escherichia colifueron resistentes a la ampicilina, y mas de 30% a la trime-toprima-sulfametoxazol. Cuando se comparo la sensibilidad de los aislados urinarios de pacientes ambulatorios y hospitalizados, se observo una marcada diferencia en los perfiles de actividad (porcentaje de microorganismos resistentes aislados en pacientes hospitalizados frente a pacientes ambulatorios) de la gentamicina (8% frente a 2%), la norfloxacina (6% frente a 2%) y las cefalosporinas de tercera generacion (18% frente a 10%). Los aislados de Klebsiella pneumoniaerecuperados de hemocultivos presentaron resistencia a las cefalospo-rinas de tercera generacion y a la gentamicina en 71 y 60% de los casos, respectivamente. La proporcion de Staphylococcus aureusresistentes a la oxacilina fue de 39%. Cerca de la mitad de los aislados de Enterococcusspp. presentaron resistencia de alto nivel a los aminoglucosi-dos, pero no se detecto resistencia a los glicopeptidos. En nuestro medio, la ampicilina y la tri-metoprima-sulfametoxazol no fueron apropiadas para el tratamiento de las diarreas; Shigella flexneripresento mayor porcentaje de aislados resistentes a ambos farmacos (87 y 74%, res-pectivamente) que Shigella sonnei(47 y 71%, respectivamente). Se detecto resistencia a las cefalosporinas de tercera generacion en 40% de los aislados de Salmonella spp. recuperados en hospitales pediatricos. En casos de meningitis bacteriana, las tasas de resistencia de Strep-tococcus pneumoniaea la penicilina (18%) y de Haemophilus influenzaea la ampicilina (19%) se situaron en el rango intermedio de las descritas en paises americanos y europeos.


Revista chilena de pediatría | 2004

Infecciones invasivas por Streptococcus pneumoniae: Estudio epidemiológico e importancia del desarrollo de un sistema de vigilancia

Raúl Ruvinsky; Angela Gentile; Mabel Regueira; Alejandra Corso; Julio Pace; Julia Bakir; José Luis Di Fabio; Alicia Rossi; Marta Altschuler; Silvia González Ayala; Claudia Hernández; Etelvina Rubeglio; Rosa Bologna; Sara Grenón; Marta Von Specht; Claudia Mayoral; Juan Carlos Beltramino; Laura Carabajal; Raquel Silverberg; María José Rial; Nora Alarcón; Fernando Ferrero; Susana Yudowski; Miguel Tregnaghi; Laura Balbi de Aguirre; Ernestina Q. Aprá; Mabel Vázquez; Laura Galanternic; Adriana Procopio; Daniel Logarzo

Las infecciones invasivas por streptococcus pnneumoniae(Spn)producen mortalidad elevada en paises en desarrollo,con tasa entre 4 y 100 veces mayores que las de Estados Unidos o Canada.Es el primer agente causal de neumonia en la infancia y de meningitis fuera de los brotes epidemicos po neisseria meningiditis.La OPS,a traves del grupo SIREVA,dedicado al desarrollo de vacunas en Latinoamerica,organizo un programa de vigilancia de infecciones invasivas por Spn en seis paises:argentina,Brasil,chile,colombia,Mexico y Uruguay iniciado en 1993 y que continua actualmente.En Argentina participan en la actualidad mas de 20 centros hospitalarios distribuidos en todas la areas geograficas del pais,actuando como Centro Nacional de referencia para la serotipificacion y determinacion de la resistencia a los antibioticos el Instituto ANLIS uDr.Carlos G Malbran.Objetivos.1)determinar los serotipos predominates,su resistencia a los antibioticos y los cambios temporales en infecciones invasivas por Spn de ninos menores de 5 anos de edad.2)Obtener informacion confiable para la formulacion de una vacuna conjugada adecuada para la region.Conclusiones.Un programa nacional de vigilancia de Spn invasivo fue desarrollado en Argentina y otros paises Latinoamericanos.Se identificaron por primera vez los serotipos predominantes en infecciones invasivas y se comprobo el incremento significativo de la resistencia a penicilina y otros antibioticos,similar a lo informado en casi todos los paises del mundo.Se obtuvo informacion epidemiologica valida para evaluar estrategias de prevencion en nuevas vacunas


Antimicrobial Agents and Chemotherapy | 1999

Pharmacokinetics and Pharmacodynamics of Amoxicillin-Sulbactam, a Novel Aminopenicillin–β-Lactamase Inhibitor Combination, against Escherichia coli

Carlos Bantar; Federico Nicola; H.J. Arenoso; Marcelo Galas; Liliana del Carmen Soria; Diego Dana; Alicia Rossi; Hebe Bianchini; Abel Jasovich


Medicina-buenos Aires | 1999

ACTIVIDAD IN VITRO DE TROVAFLOXACINA, OTRAS FLUOROQUINOLONAS Y DE DIFERENTES ANTIMICROBIANOS FRENTE A AISLAMIENTOS CLINICOS

Alicia Rossi; Marcelo Galas; Marta Tokumoto; Liliana Guelfand; Horacio Lopardo


Medicina-buenos Aires | 1999

[In vitro activity of trovafloxacin, of other fluoroquinolones and of related antimicrobials against clinical isolates. Grupo colaborativo WHONET-Argentina].

Alicia Rossi; Marcelo Galas; Marta Tokumoto; Liliana Guelfand; Horacio Lopardo


Bol. Soc. Venez. Microbiol | 1999

Manual de procediemientos y control de calidad de antibiograma con discos

Alicia Rossi; Marcelo Galas

Collaboration


Dive into the Alicia Rossi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

José Luis Di Fabio

Pan American Health Organization

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge